Trial · NCT06257537
Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
NCT06257537, Phase 2, Completed, ZetrOZ, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis. Trials, record NCT06257537. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06257537
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis
- NCT number
- NCT06257537
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 307 participants, actual
- Lead sponsor
- ZetrOZ, Inc.
- Conditions
- Osteo Arthritis Knee, Arthritis
- Interventions
- Sustained Acoustic Device with 2.5% Diclofenac Patch, Sustained Acoustic Device with 0% Diclofenac Patch, 2.5% Diclofenac Patches, SAM Patch
- First posted
- 2024-02-14
- Last updated
- 2026-06-30
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain From Baseline | Through study completion, average of 24 weeks. | Change in the self-described pain units on a scale by patient at baseline and post-treatment. |
| Primary | Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Through study completion, average of 24 weeks. | WOMAC questionnaire will be utilized (Western Ontario and McMaster Universities Arthritis Index) at baseline and post-treatment to calculate the change in scores. WOMAC was divided into 3 categories: pain, stiffness, function and total score. The pain category consists of five scores from 0 - 4, 0 being no pain 4 is worst pain possible, for a range of 0 - 20 points. The stiffness category consists of two scores from 0 - 4, 0 being no stiffness 10 is worst stiffness possible for a range of 0 - 8 points. The function score consists of 17 scores from 0 - 4, 0 being normal function and 10 is severely limited function, for a range of 0 - 68 points. Total score is the sum of pain, stiffness, and function scores (range of 0 - 96). |
| Secondary | Change in Global Rating of Change (GROC) on a Scale (-7 to +7) | Through study completion, average of 24 weeks. | Subject-reported change in overall pain on a scale, -7 = worst, +7 = best. |
| Secondary | Change in the Pain & Sleep Questionnaire (PSQ-3) | Through study completion, average of 24 weeks. | Subject-reported rating of impact of pain on sleep on a scale from 0 no impact, to 100 greatest impact. |
| Secondary | Change in Depression Anxiety Stress Scale (DASS21) | Through study completion, average of 24 weeks. | Subject-reported measures of depression, anxiety, and stress on a scale of 0-3, 0 being not applicable, 1 meaning applicable to some degree, 2 meaning applicable often, and 3 meaning applicable most of the time. Questions are divided into three categories: depression, anxiety, and stress. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06257537
GET https://conductscience.org/api/trials/v1/NCT06257537/registered